Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Nov 10 - Nov 15
10.1016/j.cell.2016.09.014 Summary Keywords glucagon-like peptide-1, glucagon-like peptide-1 receptor agonist, glucagon, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis Citation Seghieri M, Christensen AS, Andersen A, Solini A, Knop FK and Vilsbll T (2018) Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
Our legal team will evaluate whether your injuries may be linked to GLP-1 receptor agonist drugs, explain your legal options, and guide you through filing an individual lawsuit, joining a class action, or being included in multidistrict litigation
J Nephrol
Some oncologists have started prescribing GLP-1 medications alongside standard cancer treatment, and there's early research looking at whether these drugs might one day help lower cancer risk in people with obesity, since excess weight itself is a known risk factor for over a dozen cancer types
US$ 29.15
US$ 27.34
US$ 28.26
US$ 27.24
US$ 29.35
